CK 601
Alternative Names: CK-3762601; CK-601Latest Information Update: 28 Nov 2022
At a glance
- Originator Cytokinetics
- Developer Astellas Pharma; Cytokinetics
- Class
- Mechanism of Action Troponin-tropomyosin complex stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Neuromuscular disorders
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
- 28 Nov 2022 No recent reports of development identified for preclinical development in Neuromuscular-disorders in USA
- 16 Oct 2018 Preclinical trials in Neuromuscular disorders in USA (unspecified route)